Study Models Predict Azacitidine Response in MDS

Researchers used DNA methylation patterns to build computer models that forecast which myelodysplastic syndrome patients will respond to the drug azacitidine.

Updated on Nov. 10, 2026 in Cancer

Clear unlabeled sample vials on a laboratory bench with a centrifuge softly blurred behind them in cool daylight. — Researchers used DNA methylation patterns to build computer models that predict which myelodysplastic syndrome patients will respond to azacitidine, a multicenter study of 98 patients found. AI Illustration. Upload story photo >

A multicenter study of 98 myelodysplastic syndrome (MDS) patients found that DNA methylation patterns can help predict response to azacitidine. The findings were published in the Journal of Clinical Investigation.

Why it matters

Doctors currently cannot reliably predict which MDS patients will respond to treatment, and reliable biomarkers for DNA methyltransferase inhibitors have been lacking. A predictive tool could help guide treatment decisions for patients in Miami and beyond.

The study analyzed 98 MDS patients and identified seven biologically distinct groups, with 71% of Cluster VI patients responding to azacitidine. Further research is needed before these findings can guide routine clinical care.

The players

Sylvester Comprehensive Cancer Center

A cancer center at the University of Miami Miller School of Medicine where the study researchers work, known for cancer research and patient care in South Florida.

University of Miami Miller School of Medicine

The medical school whose researchers led the multicenter study on DNA methylation and azacitidine response in myelodysplastic syndrome.

The details

Researchers analyzed DNA mutations, chemical marks on DNA, and gene activity, grouping patients by methylation patterns before building and testing predictive computer models. Some of the strongest predictive signals came from regulatory regions beyond traditionally studied DNA parts.

November 9, 2026: Study findings announced by University of Miami Sylvester researchers

COVID-19
Nov. 7
Long COVID Mice Show Fibroid-Like Uterine Lesions

Health Landscape

The study builds on the long-standing use of azacitidine, a DNA methyltransferase inhibitor, in MDS treatment, where reliable response biomarkers have been absent. It shifts the focus toward DNA methylation as a more informative predictor than gene activity alone.

If validated, a predictive test could help patients with MDS avoid azacitidine when it is unlikely to work and pursue alternatives sooner. Until further research confirms these findings, current treatment decisions will remain unchanged.

The takeaway

Predicting which patients benefit from azacitidine could spare MDS patients ineffective treatment. Patients should discuss biomarker testing and treatment options with their oncologists.